Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod tablets for active primary Sjögren's syndrome
CTR20202385Phase 2Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iguratimod in primary Sjögren's syndrome, sponsored by Simcere Pharmaceutical Group. Started Apr 2021; status: active.
02
Drugs
iguratimod
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on CTR20202385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202385.